Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

Inclusion Criteria: * Patient aged from 45 to 80 years old * Life expectancy \>10 years at the inclusion time * Patient diagnosed with an intermediate-risk prostate cancer, defined by: * A T1c or T2a clinical stage * A unique cancer focus of Gleason (3+4) (Grade Group 2). In addition to the index lesion intended for treatment, the presence of additional microfoci \< 10mm on mpMRI, for which biopsies present no evidence of cancer or a Gleason score of 3+3, is accepted * A PSA level \<20 ng/mL * Cancer focus identified on a multiparametric MRI of the prostate no more than 3 months before inclusion * Confirmation of the suspicion of cancer identified on the MRI with transrectal or transperineal targeted and systematic biopsies performed with the KOELIS TRINITY system (no more than 3 months before inclusion) * Patient suitable for IV sedation or general anesthesia and focal microwave ablation * No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up * Known coagulopathy or bleeding disorders are controlled * Free, informed and written consent, dated and signed before the enrollment and before any exam required by the trial * Patient affiliated to social security regimen or beneficiary of such regimen for local regions Exclusion Criteria: * Past medical history of prostate surgery * Past medical history of radiotherapy or pelvic trauma * Past medical history of acute prostatitis * Presently taking hormonal manipulation or androgen supplements. * Past medical history of cancer in the 5 previous years, excluding a non-metastatic basal cell carcinoma of the skin * Severe BPH-related urinary tract symptoms, defined by an IPSS score \>18 * Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit * Contraindications for MRI exam * Extracapsular cancer extension or seminal vesicles or pelvic lymph node invasion suspected on prostate MRI * Presence of two or more clinically significant cancer foci in the inclusion biopsy exam * Presence of a clinically significant cancer with a Gleason score ≥8 (Grade Group ≥4) * Tumor largest axis \>15 mm on the prostate MRI * Distance between the cancer focus and the apex \<5 mm on the prostate MRI * Distance between the cancer focus and the rectum \<5 mm on the prostate MRI * Patient already participating in an interventional clinical trial * Patient protected by law